The recovery time‐course of CYP3A after induction by St John's wort administration
Open Access
- 20 February 2008
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 65 (5) , 701-707
- https://doi.org/10.1111/j.1365-2125.2008.03120.x
Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • St John's wort causes the induction of CYP3A. Little is known about how long the effect remains after cessation of St John's wort. WHAT THIS STUDY ADDS • The in vivo CYP3A activity returns progressively to the basal level approximately 1 week after cessation of St John's wort administration AIMS To examine the recovery time course of CYP3A after enzyme induction by St John's wort administration. METHODS The subjects were 12 healthy men, aged 20–33 years. On the first day, they received an oral dose of midazolam 5 mg without St John's wort (day −14). From the next day, they took St John's wort for 14 days. On the last day of St John's wort treatment (day 0) and 3 and 7 days after completion of St John's wort treatment (days 3 and 7), they received the same dose of midazolam. On each day, blood samples were obtained until 8 h after midazolam administration. Plasma concentrations of midazolam were measured by HPLC. Pharmacokinetic parameters of midazolam were determined using noncompartmental analysis. RESULTS Apparent oral clearance of midazolam was significantly increased after St John's wort administration from 65.3 ± 8.4 l h−1 (day −14) to 86.8 ± 17.3 l h−1 (day 0). It returned to the control level 7 days after the completion of St John's wort (day 7, 59.7 ± 3.8 l h−1). No significant difference in the elimination half‐life between the four periods of the study was observed. The changes in apparent oral clearance after St John's wort discontinuation indicated that CYP3A activity recovers from enzyme induction with an estimated half‐life of 46.2 h. CONCLUSIONS CYP3A activity induced by St John's wort administration progressively returns to the basal level after approximately 1 week. This finding may provide useful information to avoid clinically significant interactions of St John's wort with CYP3A substrates.Keywords
This publication has 27 references indexed in Scilit:
- Effect of the Treatment Period With Erythromycin on Cytochrome P450 3A Activity in HumansThe Journal of Clinical Pharmacology, 2007
- Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivoClinical Pharmacology & Therapeutics, 2005
- Drug interaction between St John's Wort and quazepamBritish Journal of Clinical Pharmacology, 2004
- Interaction of St John's wort with conventional drugs: systematic review of clinical trialsBMJ, 2004
- Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and womenPharmacogenetics, 2003
- Pharmacokinetic Interactions with RifampicinClinical Pharmacokinetics, 2003
- Oral Bioavailability of Hyperforin from Hypericum Extracts in Rats and Human VolunteersPharmacopsychiatry, 1998
- Differential Induction of Prehepatic and Hepatic Metabolism of Verapamil by RifampinHepatology, 1996
- St John's wort for depression--an overview and meta-analysis of randomised clinical trialsBMJ, 1996
- Influence of Food on Midazolam AbsorptionThe Journal of Clinical Pharmacology, 1986